The efficacy and safety of many PD-1/PD-L1 inhibitors have previously been demonstrated in patients with refractory for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). This evidence concerns the gene CD274 and nasopharyngeal carcinoma.